Acquisition of postbiotics pioneer Adare Biome completed

Date: 04.07.2023Source: dsm-firmenich

dsm-firmenich has confirmed the completion of its acquisition of Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million. This transaction represents an estimated 2023 EV/EBITDA multiple of 18x.

Said Philip Eykerman, President Health, Nutrition & Care, dsm-firmenich: “Adare Biome, as a global leader in the research and manufacturing of postbiotics with over a century of pioneering science in its heritage, is a perfect fit for dsm-firmenich that will complement three of our four Business Units. The Adare Biome teams will greatly help in driving our ‘Health from the Gut’ strategy and enable us to accelerate the creation of next-generation biotics to support the health of people and animals. We are excited about the new opportunities this move will unlock, as dsm-firmenich’s strong global presence and reach in local markets will enable us to deliver Adare Biome products to customers in a faster, more efficient way to bring the proven benefits of postbiotics to a wider range of people around the world.”

The company intends to extend the availability of Adare Biome’s over the counter postbiotic supplement for relieving gut upsets Lactéol® through its B2C unit, i-Health. Further development of postbiotic B2B ingredients will include opportunities in dietary supplements, early life nutrition, medical nutrition, and nutritional improvement for the under-nourished. The acquisition of Adare Biome will also position dsm-firmenich as a leader in the growing microbiome management market for pets and expand its animal health range, where the stability of postbiotics means they can be incorporated into premix feed solutions.

Concluded Tom Sellig, CEO, Adare Pharma Solutions: “dsm-firmenich is the ideal company to take Adare Biome to the next level and realise the growth potential of postbiotics. They have the infrastructure, together with strong commercialisation and science capabilities, to scale the significant scientific research that we’ve achieved over the years. Moreover, dsm-firmenich’s purpose of bringing progress to life resonates strongly with the team. We look forward to contributing to the realisation of this purpose as part of the dsm-firmenich family.” For more visit dsm-firmenich.com

David Cox / IDM

Print article (with images) Print article (without images)


Always stay up to date and sign up for our newsletter service: